Key result
Left atrial stiffness and NT-proBNP predict HFpEF mortality, with stiffness linked to ~81% higher risk.
Why the study?
Heart failure with preserved ejection fraction is associated with high morbidity and mortality, prompting an evaluation of the prognostic value of left atrial stiffness, exercise tolerance, and selected biomarkers.
Do left atrial stiffness, exercise intolerance, and injury biomarkers predict adverse outcomes in patients with HFpEF?
Cohort (n=43)
Do left atrial stiffness, exercise intolerance, and injury biomarkers predict adverse outcomes in patients with HFpEF?
Left atrial stiffness, NT-proBNP, exercise intolerance, and GDF-15 are independent predictors of mortality and hospitalizations in patients with HFpEF.
Answers are grounded in this paper and cite their sources.
LA stiffness and NT-proBNP were associated with mortality in HFpEF; leaves open whether they refine risk stratification.
Heart failure with preserved ejection fraction (HFpEF) is a complex condition associated with high morbidity and mortality. This exploratory study aimed to assess the prognostic value of left atrial (LA) stiffness, exercise tolerance, and selected biomarkers in patients with HFpEF. We evaluated LA mechanics using 2D speckle tracking in 43 patients (mean age 77.2 years) from the OPTIMISE HFpEF study (NCT03617848). Biomarkers such as N-terminal pro brain-type natriuretic peptide, growth differentiation factor 15, and galectin-3 were measured. Patients also completed a six-minute walk test. Over a mean follow-up of 24.5 months, there were five deaths (11.4%) and 21 all-cause hospitalizations (48.8%). LA stiffness (HR 1.81; p=0.028) and N-terminal pro brain-type natriuretic peptide (HR 1.01; p=0.013) were independent mortality predictors. For hospitalizations, six-minute walk distance (HR 0.99; p=0.011) and growth differentiation factor 15 (HR 1.01; p=0.007) were significant independent predictors. This exploratory analysis indicates that LA stiffness, N-terminal pro brain-type natriuretic peptide, exercise intolerance, and growth differentiation factor 15 independently predict adverse events in HFpEF. Implementing a comprehensive therapeutic approach including lifestyle modifications, medical therapy, and, if necessary, more advanced interventions to improve LA mechanics, functional capacity and clinical biomarkers may improve outcomes for HFpEF patients.
No takes yet. Share an insight, caveat, or question.
Cheriyan et al. (2026) conducted a cohort in Heart failure with preserved ejection fraction (HFpEF) (n=43). Left atrial stiffness was evaluated on Mortality (HR 1.81, p=0.028). Left atrial stiffness and NT-proBNP independently predicted mortality in patients with HFpEF over a mean follow-up of 24.5 months.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: